SPOTLIGHT: CytRx stock plunges on trial halt

Shares of CytRx plunged on the news that the FDA had halted a mid-stage trial for a drug to treat Lou Gehrig's disease. Regulators want to take some time to analyze results from animal studies of arimoclomol. CytRx stock was down 38 percent on a rough day. Release | Report

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.